Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.

Date publication

mars 2023

Journal

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher

Tous les auteurs :
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36881202

Résumé

The optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma (OGA) remains challenging.

Mots clés

HER2, Maintenance therapy, Oeso-gastric cancer, Reintroduction therapy, Trastuzumab

Référence

Gastric Cancer. 2023 03 7;: